Retatrutide
Triple-target peptide API revolutionizing metabolic disease treatment. Simultaneous activation of GLP-1R, GIPR, and GCGR delivers unprecedented efficacy in glucose control and weight management.
Retatrutide (development code LY3437943) is a first-in-class triple hormone receptor agonist peptide developed by Eli Lilly and Company, designed for the treatment of obesity and type 2 diabetes. It simultaneously activates three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG), delivering unprecedented synergistic effects on body weight reduction, glycemic control, and metabolic health.
| CAS | 2381089-83-2 |
| Molecular Formula | C₂₂₃H₃₄₈N₆₈O₇₅ |
| Molecular Weight | 4775.42 g/mol |
| Category | GLP-1 & Incretin Metabolic Peptides |
| Purity | >=99% (HPLC) |
| Status | GMP-compliant, FDA-ready |
| Applications | Severe obesity, refractory diabetes, metabolic syndrome |
| CAS | 2381089-83-2 |
|---|---|
| Applications | Refractory diabetes, Severe obesity, Triple agonist, weight management |
Related products
-
Triptorelin Acetate
CAS: 57773-63-4Applications: Assisted Reproduction, Endometriosis, Precocious Puberty, Uterine Fibroids -
Lixisenatide
CAS: 320367-13-3Applications: postprandial glucose control, Short-acting GLP-1, Type 2 diabetes -
Mazdutide
CAS: 2259884-03-0Applications: metabolic syndrome, Overweight treatment, Type 2 diabetes -
Pramlintide
CAS: 196078-30-5